Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor currently used in the treatment of Myelofibrosis (MF). Ruxolitinib confirmed improvements in splenomegaly, MF-related symptoms and survival benefit in COMFORT and JUMP studies. At present, the real-world data on the efficacy and safety of ruxolitinib in the treatment of MF in China is still insufficient. The aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with MF and to provide guidance for the usage of ruxolitinib in MF in China.This was a retrospective, multicenter study of MF patients who received ruxolitinib treatment in Shandong province from August 2012 to December 2021. Data were analyzed using SPSS. Overall survival (OS) and Event-free survival (EFS) were estimated using the Kaplan- Meier method.
Study Type
OBSERVATIONAL
Enrollment
130
The proportion of patients with a ≥35% reduction in palpable spleen volume from baseline.
Reduction in spleen volume is measured by magnetic resonance imaging/computerized tomography (MRI/CT).
Time frame: From Week 0 through Week 24
The proportion of patients with ≥50% reduction in Total Symptom Score (TSS) from baseline.
TSS is assessed by the MPN-10.
Time frame: From Week 0 through Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.